Jae Lyun Lee

Title: Innovations in Cancer Treatment by Jae Lyun Lee

Introduction

Jae Lyun Lee is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of cancer treatment through his innovative research and patent developments. His work focuses on the suppression of cancer metastasis, which is a critical area in oncology.

Latest Patents

Jae Lyun Lee holds a patent for a composition aimed at the treatment or metastasis suppression of cancers. This composition includes a p34 expression inhibitor or activity inhibitor as an active ingredient. The invention details how the knock-down of the p34 protein leads to monoubiquitination of PTEN, inducing its nuclear localization. This process inhibits the Akt pathway, which is associated with tumor survival, proliferation, and metastasis. As a result, the invention significantly reduces the clonogenic potential and tumor-forming ability of various cancer cells that express both PTEN and NEDD4-1. This innovative approach positions the p34 gene expression inhibitor or p34 protein activity inhibitor as a promising treatment or metastasis suppression agent for cancers.

Career Highlights

Throughout his career, Jae Lyun Lee has worked with reputable organizations, including the Asan Foundation and the University of Ulsan Foundation for Industry Cooperation. His experience in these institutions has allowed him to collaborate with other experts in the field and further his research in cancer treatment.

Collaborations

One of his notable collaborators is Dong Hoon Jin, with whom he has worked on various projects related to cancer research and treatment innovations.

Conclusion

Jae Lyun Lee's contributions to cancer treatment through his innovative patent highlight the importance of research in developing effective therapies. His work continues to inspire advancements in the medical field, particularly in oncology.